{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:10:08Z","timestamp":1756458608019,"version":"3.44.0"},"reference-count":47,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Despite evidence of racial\/ethnicity health inequities in oral anticoagulant initiation and clinical outcomes for nonvalvular atrial fibrillation, little is known about disparities in treatment patterns, particularly discontinuation and switching.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            This retrospective study utilized Komodo Healthcare Map data (1\u00a0July 2018 to 30\u00a0June 2023) to examine treatment patterns in patients with nonvalvular atrial fibrillation initiating direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran) versus warfarin, stratified by self-reported race\/ethnicity (White, Black\u00a0and Hispanic) in the USA. Inverse probability of treatment weighting balanced baseline covariates and Cox model computed adjusted hazard ratio (aHR) and 95% confidence interval (CI)\u00a0for apixaban-warfarin and DOAC-warfarin comparisons in the overall cohort and by race\/ethnicity.\n            <jats:bold>Results:<\/jats:bold>\n            In the apixaban-warfarin cohort, apixaban patients were 24% less likely to discontinue treatment (aHR: 0.76, 95% CI: 0.75\u20130.77) and 79% less likely to switch to another oral anticoagulant (aHR: 0.21, 95% CI: 0.20\u20130.22) versus warfarin. By race\/ethnicity, a higher proportion of Black patients discontinued than White and Hispanic (68, 60\u00a0and 63%, respectively). Almost 5% of apixaban patients switched to another oral anticoagulant versus 31% on warfarin. Among warfarin switchers, 77% initiated apixaban (80% in White; 76% Black; 76% in Hispanic patients). The DOAC-warfarin cohort followed similar trends.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Overall, apixaban\/DOACs were associated with more favorable treatment patterns than warfarin. However, racial\/ethnicity differences were observed. Given the potential impact of oral anticoagulant discontinuation on clinical outcomes, further research is needed to better understand factors contributing to higher discontinuation and switch rates, particularly among Black and Hispanic patients.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0057","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:27:34Z","timestamp":1754400454000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race\/ethnicity"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0038-2421","authenticated-orcid":false,"given":"Michelle","family":"Zhang","sequence":"first","affiliation":[{"name":"Bristol-Myers Squibb Company, Lawrenceville, NJ 08648, USA"},{"name":"University of Southern California, Los Angeles, CA 90007, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risho","family":"Singh","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken, PA 19428, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samina","family":"Dhuliawala","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken, PA 19428, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Stafkey","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken, PA 19428, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Vodicka","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT 06340, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Lawrenceville, NJ 08648, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandkumar","family":"Dubey","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Lawrenceville, NJ 08648, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Lawrenceville, NJ 08648, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"24","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.jacc.2019.10.040","article-title":"Ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week","volume":"74","author":"Alkhouli M","year":"2019","unstructured":"Alkhouli M, Friedman PA. Ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week. J. Am. Coll. Cardiol. 74(24), 3050\u20133065 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla S","year":"2013","unstructured":"Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 112(8), 1142\u20131147 (2013).","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"e002776","DOI":"10.1161\/JAHA.115.002776","article-title":"Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions","volume":"5","author":"Di Biase L","year":"2016","unstructured":"Di Biase L. Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J. Am. Heart Assoc. 5(2), e002776 (2016).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej J","year":"2020","unstructured":"Kornej J, Borschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ. Res. 127(1), 4\u201320 (2020).","journal-title":"Circ. Res."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee Members","year":"2024","unstructured":"Writing Committee Members, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 83(1), 109\u2013279 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"107602962095255","DOI":"10.1177\/1076029620952550","article-title":"National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes and practice of cardiologist to PCPs","volume":"26","author":"Saeed H","year":"2020","unstructured":"Saeed H, Ovalle OG, Bokhary U, Jermihov A, Lepkowska K, Bauer V National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes and practice of cardiologist to PCPs. Clin. Appl. Thromb. Hemost. 26, 1076029620952550 (2020).","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"12","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1007\/s11606-020-06180-8","article-title":"Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared with warfarin","volume":"35","author":"Bradley M","year":"2020","unstructured":"Bradley M, Welch EC, Eworuke E, Graham DJ, Zhang R, Huang TY. Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared with warfarin. J. Gen. Intern. Med. 35(12), 3597\u201333604 (2020).","journal-title":"J. Gen. Intern. Med."},{"issue":"12","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093\u20132104 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez JA","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. Brit. Med. J. 359, j5058 (2017).","journal-title":"Brit. Med. J."},{"issue":"10","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"9921","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921), 955\u2013962 (2014).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik A","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J. Thromb. Thrombolysis 43(3), 365\u2013379 (2017).","journal-title":"J. Thromb. Thrombolysis"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071907"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13985"},{"issue":"12","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"e2137288","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries","volume":"4","author":"Wheelock KM","year":"2021","unstructured":"Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries. JAMA Netw. Open 4(12), e2137288 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12325-018-0840-8","article-title":"Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States","volume":"36","author":"Baker CL","year":"2019","unstructured":"Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States. Adv. Ther. 36(1), 162\u2013174 (2019).","journal-title":"Adv. Ther."},{"issue":"6","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"e020676","DOI":"10.1136\/bmjopen-2017-020676","article-title":"Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population","volume":"8","author":"Willey V","year":"2018","unstructured":"Willey V, Franchino-Elder J, Fu AC, Wang C, Sander S, Tan H Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open 8(6), e020676 (2018).","journal-title":"BMJ Open"},{"key":"e_1_3_8_22_2","volume-title":"European Society of Cardiology Congress","author":"Atreja N","year":"2004","unstructured":"Atreja N, Kohli M, Hines DM, Jiang J, Hagan M, Aweh G Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries. Poster ESC 85570. Presented at: European Society of Cardiology Congress, London, United Kingdom of Great Britain and Northern Ireland (2004)."},{"issue":"4","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jcm13041073","article-title":"Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation","volume":"13","author":"Deitelzweig S","year":"2024","unstructured":"Deitelzweig S, Kang A, Jiang J, Gao C, Luo X, Atreja N Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation. J. Clin. Med. 13(4), 1073 (2024).","journal-title":"J. Clin. Med."},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"113002","DOI":"10.1016\/j.biopha.2022.113002","article-title":"Use of anticoagulant drugs in patients with atrial fibrillation. Does adherence to therapy have a prognostic impact?","volume":"150","author":"Toma MM","year":"2022","unstructured":"Toma MM, Bungau SG, Tit DM, Moisi MI, Bustea C, Vesa CM Use of anticoagulant drugs in patients with atrial fibrillation. Does adherence to therapy have a prognostic impact? Biomed. Pharmacother. 150, 113002 (2022).","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4070\/kcj.2019.0234","article-title":"Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal","volume":"49","author":"Lowres N","year":"2019","unstructured":"Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ. J. 49(10), 883\u2013907 (2019).","journal-title":"Korean Circ. J."},{"issue":"9","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14740338.2017.1351542","article-title":"Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation","volume":"16","author":"Rivera-Caravaca JM","year":"2017","unstructured":"Rivera-Caravaca JM, Esteve-Pastor MA, Roldan V, Marin F, Lip GYH. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opin. Drug Saf. 16(9), 1051\u20131062 (2017).","journal-title":"Expert Opin. Drug Saf."},{"key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ahj.2020.04.016","article-title":"Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)","volume":"226","author":"Jackson LR","year":"2020","unstructured":"Jackson LR 2nd, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am. Heart J. 226, 85\u201393 (2020).","journal-title":"Am. Heart J."},{"issue":"10","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"e0291575","DOI":"10.1371\/journal.pone.0291575","article-title":"Quality of life among patients with atrial fibrillation: a theoretically-guided cross-sectional study","volume":"18","author":"Rush KL","year":"2023","unstructured":"Rush KL, Seaton CL, Burton L, Loewen P, O'Connor BP, Moroz L Quality of life among patients with atrial fibrillation: a theoretically-guided cross-sectional study. PLOS ONE 18(10), e0291575 (2023).","journal-title":"PLOS ONE"},{"issue":"1","key":"e_1_3_8_29_2","first-page":"103","article-title":"Race\/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data","volume":"112","author":"Essien UR","year":"2020","unstructured":"Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race\/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data. J. Natl Med. Assoc. 112(1), 103\u2013108 (2020).","journal-title":"J. Natl Med. Assoc."},{"issue":"22","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar AM","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, Shah NP, Rousseau JF, Flaker GC Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J. Am. Heart Assoc. 11(22), e026723 (2022).","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamacardio.2016.1025","article-title":"Racial differences in atrial fibrillation-related cardiovascular disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"1","author":"Magnani JW","year":"2016","unstructured":"Magnani JW, Norby FL, Agarwal SK, Soliman EZ, Chen LY, Loehr LR Racial differences in atrial fibrillation-related cardiovascular disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol. 1(4), 433\u2013441 (2016).","journal-title":"JAMA Cardiol."},{"issue":"3","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hroo.2022.11.004","article-title":"Sociodemographic determinants of oral anticoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning","volume":"4","author":"Azizi Z","year":"2023","unstructured":"Azizi Z, Ward AT, Lee DJ, Gad SS, Bhasin K, Beetel RJ Sociodemographic determinants of oral anticoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning. Heart Rhythm O2 4(3), 158\u2013168 (2023).","journal-title":"Heart Rhythm O2"},{"issue":"12","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamacardio.2022.3704","article-title":"Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: Findings from the Get With The Guidelines-Atrial Fibrillation Registry","volume":"7","author":"Essien UR","year":"2022","unstructured":"Essien UR, Chiswell K, Kaltenbach LA, Wang TY, Fonarow GC, Thomas KL Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: Findings from the Get With The Guidelines-Atrial Fibrillation Registry. JAMA Cardiol. 7(12), 1207\u20131217 (2022).","journal-title":"JAMA Cardiol."},{"issue":"6","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"e1004003","DOI":"10.1371\/journal.pmed.1004003","article-title":"Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: a cohort study","volume":"19","author":"Ajabnoor AM","year":"2022","unstructured":"Ajabnoor AM, Zghebi SS, Parisi R, Ashcroft DM, Rutter MK, Doran T Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: a cohort study. PLOS Med. 19(6), e1004003 (2022).","journal-title":"PLOS Med."},{"key":"e_1_3_8_35_2","unstructured":"Komodo Health Inc. Healthcare map [cited: 27 November 2024]. Available from: https:\/\/www.komodohealth.com\/technology\/healthcare-map\/"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0005"},{"issue":"10","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"e031342","DOI":"10.1136\/bmjopen-2019-031342","article-title":"Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK","volume":"9","author":"Ruigomez A","year":"2019","unstructured":"Ruigomez A, Vora P, Balabanova Y, Brobert G, Roberts L, Fatoba S Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. BMJ Open 9(10), e031342 (2019).","journal-title":"BMJ Open"},{"issue":"25","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.jacc.2021.04.110","article-title":"Racial and ethnic considerations in patients with atrial fibrillation: JACC Focus Seminar 5\/9","volume":"78","author":"Norby FL","year":"2021","unstructured":"Norby FL, Benjamin EJ, Alonso A, Chugh SS. Racial and ethnic considerations in patients with atrial fibrillation: JACC Focus Seminar 5\/9. J. Am. Coll. Cardiol. 78(25), 2563\u20132572 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.hrthm.2018.05.019","article-title":"Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review","volume":"15","author":"Ugowe FE","year":"2019","unstructured":"Ugowe FE, Jackson LR 2nd, Thomas KL. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review. Heart Rhythm. 15(9), 1337\u20131345 (2019).","journal-title":"Heart Rhythm."},{"issue":"2","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"Banerjee A","year":"2020","unstructured":"Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart 106(2), 119\u2013126 (2020).","journal-title":"Heart"},{"issue":"11","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.acvd.2022.06.006","article-title":"Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: a French comprehensive nationwide study","volume":"115","author":"Danchin N","year":"2022","unstructured":"Danchin N, Steg G, Mahe I, Hanon O, Jacoud F, Nolin M Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: a French comprehensive nationwide study. Arch. Cardiovasc. Dis. 115(11), 571\u2013577 (2022).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"4","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"e0195950","DOI":"10.1371\/journal.pone.0195950","article-title":"Discontinuation risk comparison among \u2018real-world\u2019 newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban","volume":"13","author":"Lip GYH","year":"2018","unstructured":"Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C Discontinuation risk comparison among \u2018real-world\u2019 newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban. PLOS ONE 13(4), e0195950 (2018).","journal-title":"PLOS ONE"},{"issue":"5","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"e249465","DOI":"10.1001\/jamanetworkopen.2024.9465","article-title":"Racial and ethnic disparities in initiation of direct oral anticoagulants among Medicare beneficiaries","volume":"7","author":"Reynolds KR","year":"2024","unstructured":"Reynolds KR, Khosrow-Khavar F, Dave CV. Racial and ethnic disparities in initiation of direct oral anticoagulants among Medicare beneficiaries. JAMA Netw. Open 7(5), e249465 (2024).","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/j.cjco.2021.09.004","article-title":"Racial and ethnic differences in the management of atrial fibrillation","volume":"3","author":"Tamirisa KP","year":"2021","unstructured":"Tamirisa KP, Al-Khatib SM, Mohanty S, Han JK, Natale A, Gupta D Racial and ethnic differences in the management of atrial fibrillation. CJC Open 3(Suppl. 12), S137\u2013S148 (2021).","journal-title":"CJC Open"},{"issue":"2","key":"e_1_3_8_45_2","first-page":"e28","article-title":"Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: a retrospective cohort study","volume":"27","author":"Holbrook A","year":"2020","unstructured":"Holbrook A, Morrow R, Lee AYY, Foster G, Pullenyegum E. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: a retrospective cohort study. J. Popul. Ther. Clin. Pharmacol. 27(2), e28\u2013e44 (2020).","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"issue":"3","key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40256-021-00501-w","article-title":"Non-persistence to oral anticoagulation treatment in patients with non-valvular atrial fibrillation in the USA","volume":"22","author":"Dhamane AD","year":"2022","unstructured":"Dhamane AD, Hernandez I, Di Fusco M, Gutierrez C, Ferri M, Russ C Non-persistence to oral anticoagulation treatment in patients with non-valvular atrial fibrillation in the USA. Am. J. Cardiovasc. Drugs 22(3), 333\u2013343 (2022).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15021"},{"issue":"1","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40119-024-00395-0","article-title":"Impact of social determinants of health on primary adherence of oral anticoagulants among patients with newly diagnosed atrial fibrillation","volume":"14","author":"Glowacki N","year":"2025","unstructured":"Glowacki N, Guzman I, Mills JR, Parks A, Ateya M, Dai F Impact of social determinants of health on primary adherence of oral anticoagulants among patients with newly diagnosed atrial fibrillation. Cardiol. Ther. 14(1), 53\u201369 (2025).","journal-title":"Cardiol. Ther."},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12030020"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:53:28Z","timestamp":1756457608000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0057"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0057","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250057"}}